Allogeneic hematopoietic stem cell transplant in HIV-infected patients resulted in long-term reduction of HIV reservoirs.
A persistent reservoir of cells containing latent HIV virus contributes to rebound viremia upon discontinuation of combination antiretroviral therapy (ART). Allogeneic hematopoietic stem cell transplantation (allo-HSCT) from a donor with a homozygous mutation in the CCR5 coreceptor produced the only known cure of HIV. Now, European investigators report outcomes of allo-HSCT from CCR5 wild-type donors in six HIV-infected participants.
All patients had complete remission of their hematologic disease, maintained use of ART, and were alive at 2 years after transplantation. Five participants demonstrated complete chimerism with a peripheral-blood progenitor-cell graft source and had undetectable HIV reservoirs. The sixth participant showed mixed …
Reviewing Authors
DisclosuresGrant/Research SupportNIH/National Institute of Allergy and Infectious Diseases; NIH/National Institute on Drug Abuse
Editorial BoardsJAIDS: Journal of Acquired Immune Deficiency Syndromes; Vaccines
Leadership Positions in Professional SocietiesInternational Antiviral Society–USA (Board of Directors); Infectious Diseases Society of America (Past President)
DisclosuresGrant/Research SupportNIH/National Institute of Allergy and Infectious Diseases; NIH/National Institute on Drug Abuse
Editorial BoardsJAIDS: Journal of Acquired Immune Deficiency Syndromes; Vaccines
Leadership Positions in Professional SocietiesInternational Antiviral Society–USA (Board of Directors); Infectious Diseases Society of America (Past President)